Oncologic Drugs Advisory Committee; Cancellation, 67696 [2022-24470]
Download as PDF
<![CDATA[
67696
Federal Register / Vol. 87, No. 216 / Wednesday, November 9, 2022 / Notices
privacy, and confidentiality; and data
skill development.
The Division coordinates and
provides consultation, direction, and
support for ACF data governance
activities; conducts demonstrations and
develops tools, policies, and procedures
that support the increased accessibility
and reuse of administrative and survey
data for statistical purposes; conducts,
manages, and coordinates major crossprogram, leading-edge research,
demonstration, and evaluation studies
related to responsible data management
and use; develops policy-relevant
priorities for data collection and
analysis; manages and conducts
statistical, policy, and program analyses;
and provides consultation,
coordination, direction, and support for
research and evaluation activities
related to responsible data management
and use. The Division provides
leadership and guidance to interagency
work groups in these areas for the
Department.
IV. Continuation of Policy. Except as
inconsistent with this reorganization, all
statements of policy and interpretations
with respect to organizational
components affected by this notice
within ACF, heretofore issued and in
effect on this date of this reorganization
are continued in full force and effect.
V. Delegation of Authority. All
delegations and redelegations of
authority made to officials and
employees of affected organizational
components will continue in them or
their successors pending further
redelegations, provided they are
consistent with this reorganization.
VI. Funds, Personnel, and Equipment.
Transfer of organizations and functions
affected by this reorganization shall be
accompanied in each instance by direct
and support funds, positions, personnel,
records, equipment, supplies, and other
resources.
This reorganization will be effective
upon date of signature.
January Contreras,
Assistant Secretary, Administration for
Children and Families.
[FR Doc. 2022–24421 Filed 11–8–22; 8:45 am]
BILLING CODE 4184–01–P
khammond on DSKJM1Z7X2PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2022–N–2174]
Oncologic Drugs Advisory Committee;
Cancellation
Food and Drug Administration,
HHS.
VerDate Sep<11>2014
17:09 Nov 08, 2022
Jkt 259001
Notice.
The meeting of the Oncologic
Drugs Advisory Committee scheduled
for November 22, 2022, is canceled.
This meeting was announced in the
Federal Register of September 22, 2022.
The meeting is no longer needed.
FOR FURTHER INFORMATION CONTACT:
Joyce Frimpong, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–7973, ODAC@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting,
which was announced in the Federal
Register of September 22, 2022 (87 FR
57904).
SUMMARY:
Dated: November 3, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022–24470 Filed 11–8–22; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–E–2257]
Determination of Regulatory Review
Period for Purposes of Patent
Extension; XCOPRI
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for XCOPRI and is publishing this
notice of that determination as required
by law. FDA has made the
determination because of the
submission of an application to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of a
patent which claims that human drug
product.
SUMMARY:
Anyone with knowledge that any
of the dates as published (see the
SUPPLEMENTARY INFORMATION section) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by January 9, 2023.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
DATES:
Food and Drug Administration
AGENCY:
ACTION:
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
during the regulatory review period by
May 8, 2023. See ‘‘Petitions’’ in the
SUPPLEMENTARY INFORMATION section for
more information.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. The https://
www.regulations.gov electronic filing
system will accept comments until
11:59 p.m. Eastern Time at the end of
January 9, 2023. Comments received by
mail/hand delivery/courier (for written/
paper submissions) will be considered
timely if they are received on or before
that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand Delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2020–E–2257 for ‘‘Determination of
Regulatory Review Period for Purposes
of Patent Extension; XCOPRI.’’ Received
E:\FR\FM\09NON1.SGM
09NON1
]]>Agencies
[Federal Register Volume 87, Number 216 (Wednesday, November 9, 2022)]
[Notices]
[Page 67696]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-24470]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-2174]
Oncologic Drugs Advisory Committee; Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Oncologic Drugs Advisory Committee
scheduled for November 22, 2022, is canceled. This meeting was
announced in the Federal Register of September 22, 2022. The meeting is
no longer needed.
FOR FURTHER INFORMATION CONTACT: Joyce Frimpong, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-7973, [email protected], or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow
the prompts to the desired center or product area. Please call the
Information Line for up-to-date information on this meeting, which was
announced in the Federal Register of September 22, 2022 (87 FR 57904).
Dated: November 3, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-24470 Filed 11-8-22; 8:45 am]
BILLING CODE 4164-01-P
